Материалов:
1 082 141

Репозиториев:
30

Авторов:
761 409

По вашему запросу найдено документов: 322952

Страница 1 из 32296

Doxorubicin-induced cardiometabolic disturbances: what can we do?
Avagimyan A., Pogosova N., Rizzo M., Sarrafzadegan N.
Doxorubicin and cyclophosphamide mode of chemotherapy-related cardiomyopathy: Review of preclinical model
Avagimyan A., Kakturskiy L., Pogosova N., Ottaviani G., Rizzo M., Sarrafzadegan N.
drugs, doxorubicin (adriamycin) and cyclophosphamide (AC mode of chemotherapy) - Avagimyan A., et al
Corrigendum to "HIV-Related Atherosclerosis: State-of-the-Art-Review" [Current Problems in Cardiology, Volume 48, Issue 9, September 2023, 101783
Avagimyan A., Pogosova N., Kakturskiy L., Sheibani M., Urazova O., Trofimenko A., Navarsdyan G., Jndoyan Z., Abgaryan K., Fogacci F., Galli M., Agati L., Kobalava Z., Shafie D., Marzilli M., Gogiashvili L., Sarrafzadegan N.
Triglyceride-glucose index (TyG) as a novel biomarker in the era of cardiometabolic medicine
Avagimyan A., Pogosova N., Fogacci F., Aghajanova E., Djndoyan Z., Patoulias D., Sasso L.L., Bernardi M., Faggiano A., Mohammadifard N., Neglia D., Carugo S., Cicero A., Rizzo M., Biondi-Zoccai G., De Caterina R., Sarrafzadegan N.
accessible and reproducible gold-standard surrogate marker for insulin resistance. Ideally, such a marker
Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 2)
Avagimyan A.A., Sheibani M., Trofimenko A.I., Lysov E.E., Khamidova F.M., Aznauryan A.Z., Sukiasyan L.M., Sahakyan K.T., Gevorgyan T.R., Tatoyan M.R., Mkrtchyan G.L., Meltonyan G.L., Petrosyan A.R., Martemyanova L.A., Petrosyan R.R., Urazova O.I., Pogosova N.V., Sarrafzadegan N.
, and their effect on different organs and systems. © Ashot A. Avagimyan, Mohammad Sheibani, Artem I. Trofimenko
Doxorubicin-related cardiotoxicity: review of fundamental pathways of cardiovascular system injury
Avagimyan A., Pogosova N., Kakturskiy L., Sheibani M., Challa A., Kogan E., Fogacci F., Mikhaleva L., Vandysheva R., Yakubovskaya M., Faggiano A., Carugo S., Urazova O., Jahanbin B., Lesovaya E., Polana S., Kirsanov K., Sattar Y., Trofimenko A., Demura T., Saghazadeh A., Koliakos G., Shafie D., Alizadehasl A., Cicero A., Costabel J.P., Biondi-Zoccai G., Ottaviani G., Sarrafzadegan N.
after 6 decades of research, a conclusive solution to protect the cardiovascular system against
HIV-Related Atherosclerosis: State-of-the-Art-Review
Avagimyan A., Pogosova N., Kakturskiy L., Sheibani M., Urazova O., Trofimenko A., Navasardyan G., Jndoyan Z., Abgaryan K., Fogacci F., Galli M., Agati L., Kobalava Z., Shafie D., Marzilli M., Gogiashvili L., Sarrafzadegan N.
therapy into routine clinical practice, there was a considerable breakthrough in the treatment of HIV
Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1)
Avagimyan A.A., Sheibani M., Trofimenko A.I., Lysov E.E., Khamidova F.M., Aznauryan A.Z., Sukiasyan L.M., Sahakyan K.T., Gevorgyan T.R., Tatoyan M.R., Mkrtchyan G.L., Meltonyan G.L., Petrosyan A.R., Martemyanova L.A., Petrosyan R.R., Urazova O.I., Pogosova N.V., Sarrafzadegan N.
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged as a revolutionary class of drugs
Diabetic Cardiomyopathy: 2023 Update by the International Multidisciplinary Board of Experts
Avagimyan A., Fogacci F., Pogosova N., Kakrurskiy L., Kogan E., Urazova O., Kobalava Z., Mikhaleva L., Vandysheva R., Zarina G., Trofimenko A., Navasardyan G., Mkrtchyan L., Galli M., Jndoyan Z., Aznauryan A., Saahakyan K., Agati L., Shafie D., Cicero A., Di Salvo G., Sarrafzadegan N.
. The metabolic disorders caused by hyperglycemia, insulin resistance, and dyslipidemia, results in a cascade
Алгебры Ли и ассоциативные алгебры: учебное пособие
Корешков Н. А. (Николай Александрович), Скрябин С. М. (Сергей Маркович)

Страница 1 из 32296

Фасеты

Партнеры

КФУ
ТГУ
Elpub
СФУ
Webpublishers

Индексация

BASE
WorldCat
OpenAIRE
EDS
core